Patient-reported outcome measures in multiple sclerosis

International MS Journal

Volumn 13, Issue 3, 2006, Pages 92-99

  Riazi, Afsane ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

MS specific PRO measures; Multipie sclerosis; Patient reported outcome (PRO) measures; Psychometric criteria; Psychometric methods

Indexed keywords

HUMAN; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PSYCHOMETRY; QUALITY OF LIFE; REVIEW; SHORT FORM 36; TREATMENT OUTCOME;

HUMANS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 33845381818     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
2. Nunnally JC, Bernstein IH: Psychometric Theory, 3rd edn. New York: McGraw-Hill, 1994.
3. Sharrack B, Hughes RA, Soudain S, Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 1999; 122: 141-159.
4. Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000; 123: 1027-1040.
5. Guyatt GH, Freeny DH, Patrick DL. Measuring health-related quality of life. Ann Int Med 1993, 118: 622-629.
6. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 1997; 314: 1580-1583.
7. Committee for Medicinal Products for Human Use. Reflection Paper on the Regulatory Guidance for the Use of Health Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products. London, UK: European Medicines Agency, 2005.
8. Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, 19-22 June 1946; signed on 22 July 1946 by the representatives of 61 States (Official Records of the World Heaith Organization, no 2, p 100) and entered into force on 7 April 1948.
9. Campbell A, Converse PE, Sodgers WL The Quality of American Life. New York: Sage Foundation, 1976.
10. Patrick DL, Erickson R Health Status and Health Policy: Allocating Resources to Health Care. New York: Oxford University Press, 1993.
11. Ware JE, Jr. Conceptualization and measurement of health-related quality of life: comments on an evolving field. Arch Phys Med Rehabil 2003; 84: 43-51.
12. Essink-Bot ML, Krabbe PF, Bonsel GJ, Aaronson NK. An empirical comparison of four generic health status measures. The Nottingham Health Profile, the Medical Outcomes Study 30-item Short-Form Health Survey, the COOP/WONCA charts, and the EuroQol instrument. Med Care 1997; 35; 522-537.
13. Ware JE, Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: Nimrod Press, 1993.
14. Riazi A, Hobart JC, Lamping DL, Firzpatrick R, Freeman JA, jenkinson C et al. Using the SF-30 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles. J Neurol Neurosurg Psychiatry 2003; 74: 710-714.
15. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well-being for individuals with Parkinson's Disease. Qual Life Res 1995; 4: 241-248.
16. Patrick D, Deyo R. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27: S217-S232.
17. Freeman JA, Hobart JC, Langdon DW, Thompson AJ. Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 150-156.
18. Nortvedt MW, Ruse T, Myhr KM, Nyland HI. Performance of the SF-36, SF-12 and RAND-36 summary scales in a multiple sclerosis population. Med Care 2000; 38: 1022-1028.
19. Hobart JC, Freeman JA, Lamping DL, Fitzpatrick R, Thompson AJ. The SF-36 in multiple sclerosis: why assumptions must be tested. J Neurol Neurosurg Psychiatry 2001; 71: 363-370.
20. US Department of Health and Human Services. Draft Guidance For Industry: Patient-reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2006.
21. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual life Res 1995; 4: 187-206.
22. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47: 129-139.
23. Ritvo PG, Fischer JS, Miller DM, Andrews H, Paty DW, LaRocca NG. Multiple Sclerosis Quality of Life Inventory: A User's Manual. New York: National Multiple Sclerosis Society, 1997.
24. Hobart J, Lamping D, Fitzpatrick A, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001; 124: 962-973.
25. Ford HL, Gerry E, Tennant A, Whalley D, Haigh, R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil 2001; 15: 247-258.
26. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999;5:251-259.
27. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. Health Technol Assess 2004; 8: 1-48.
28. Rotstein Z, Barak Y, Noy S, Achiron A. Quality of life in multiple sclerosis: development and validation of the 'RAYS' Scale and comparison with the SF-36. Int J Qual Health Care 2000; 12: 511-517.
29. Lankhorst GJ, Jelles F, Smits RC, Polman CH, Kiuk DJ, Pfennings LE ef al. Quality of life in multiple sclerosis: the disability and impact profile (DIP). J Neurol 1996; 243: 469-474.
30. Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ. Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales. Mult Scler 2003; 9: 411-419.
31. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales. J Neurol Neurosurg Psychiatry 2005; 76: 1539-1543.
32. Nicholl CR, Lincoln NB, Francis VM, Stephan TF. Assessing quality of life in people with multiple sclerosis. Disabil Rehabil 2001; 23: 597-603.
33. Duff SB, Mordin MM. Strategies for assessing health economics and quality of life in multiple sclerosis. Expert Rev Pharmacoeconomics Outcomes Res 2002; 2: 577-587.
34. Benito-Leon J, Morales JM, Rivera-Navarro J, Mitchell A. A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil 2003; 25: 1291-1303.
35. Solari A. Role of health-related quality of life measures in the routine care of people with multiple sclerosis. Health Qual Life Outcomes 2005; 3: 16.
36. Rasch G. Probabilistic Models for Some Intelligence and Attainment Tests. Copenhagen: Danish Institute for Education Research, 1960.
37. Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PM et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 2006; 129:224-234.
38. Wainer H. Computer Adaptive Testing: A Primer. Hillsdale, NJ: Lawrence Erlbaum, 1990.
39. Virley DJ. Developing therapeutics for the treatment of multiple sclerosis. NeuroRx 2005; 2: 638-649.